secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-088203
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q4 net loss $58.8M; UP421 islet cells function at 1 year no immunosuppression; new $150M ATM filed
--------------------------------------------------------------------------------

- UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.
- Expect to file IND for SC451 (stem cell-derived islet therapy) and begin Phase 1 trial this year.
- SG293 in vivo CAR T: NHP data show deep B-cell depletion; first-in-human data expected this year.
- Q4 2025 net loss $58.8M ($0.21/shr); R&D $34.9M; cash $138.4M; runway into late 2026.
- Entered new ATM agreement with TD Cowen for up to $150M; raised $133.7M gross from equity in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/0001193125-26-088203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/sana-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-088203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer